This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: University Of Louisville Research Foundation, Inc., Biothera Inc.. Active years: 2013-2016.
Company Filing History:
3 out of 398 
1 out of 15 Years Active: 2013-2016
Title: Gordon D. Ross: Innovator in Cancer Therapy
Introduction
Gordon D. Ross is a notable inventor based in Prospect, Kentucky, who has made significant contributions to the field of cancer therapy. With a focus on utilizing beta glucan and antibodies, he has developed innovative methods aimed at enhancing antitumor responses. His work has led to the issuance of three patents, reflecting his commitment to advancing medical science.
Latest Patents
One of Gordon D. Ross's latest patents involves cancer therapy using beta glucan and antibodies. This invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble Beta (1,3; 1,6) glucan (NSG) enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. Notably, the glucan does not stimulate the induction of inflammatory cytokines. Additionally, the patent describes methods of using whole glucan particles (WGP) as an immunomodulator, which induces a shift from a Th2 response to a Th1 response, leading to an enhanced antitumor cytotoxic T-cell response.
Career Highlights
Throughout his career, Gordon D. Ross has worked with esteemed organizations, including the University of Louisville Research Foundation, Inc. and Biothera Inc. His experience in these institutions has allowed him to collaborate with other professionals in the field, furthering his research and development efforts.
Collaborations
Gordon D. Ross has collaborated with Gary R. Ostroff, contributing to the advancement of cancer therapy research. Their partnership has been instrumental in exploring innovative approaches to treatment.
Conclusion
Gordon D. Ross stands out as an inventor dedicated to improving cancer therapies through his innovative use of beta glucan and antibodies. His patents and collaborations reflect his significant impact on the field of medical research.